Skip to main content

Table 2 Relationship between TILs, PD-L1, and clinicopathological characteristics in post-neoadjuvant breast cancer cases

From: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance

 

TIL status

 

PD-L1 status

 

Positive (N = 50)

Negative (N = 8)

p value

Positive (N = 10)

Negative (N = 48)

p value

Age

  < 50 years

22

6

0.103

8

20

0.027a

 >50 years

28

2

 

2

28

 

Size at surgery

  < 2 cm

19

5

0.191

7

17

0.043a

  > 2 cm

31

3

 

3

31

 

Histotype

 Ductal

43

7

0.909

8

42

0.53

 Other

7

1

 

2

6

 

Grade

 1 and 2

32

6

0.697

3

33

0.45

 3

20

2

 

6

15

 

Lymph node status

 Positive

32

5

0.934

8

29

0.241

 Negative

18

3

 

2

19

 

Hormone receptor status

 Positive

39

7

0.599

8

38

0.497

 Negative

10

1

 

1

10

 

HER2 status

 Positive

10

2

0.745

2

10

0.952

 Negative

40

6

 

8

38

 

Relapse status

 Relapse

9

2

0.37

11

0

0.159

 No relapse

23

2

 

21

4

 

 N/A

27

4

 

16

6

 

ΔTILs (pre–post)

 Positive or zero

15

5

0.01

19

1

0.206

 Negative

23

0

 

19

4

 
  1. TIL tumor infiltrating lymphocyte, PD-L1 programmed death ligand 1, HER human epidermal growth factor, N/A not available
  2. aSignificant (p < 0.05)